• Mira Smart Conferencing
  • Home
  • Table of Contents
  • Advanced Search
 
Advanced Search

Browse All

Current Filters

CLEAR FILTER x

TITLE

Session Name:

  • S32: Autoimmune Neurology: NMOSD/MOGAD

Filter

Partial Search: Partial searches may be entered manually by pressing enter in the filter input field.
Author Filter: Selecting one or more Authors from the Author drop down list will filter results by Author last name(s) only.

Displaying 1 - 5 of 10

  • Page:
  • 1
  • 2

Long-term Comparative Efficacy of Inebilizumab in the AQP4+ Subpopulation from N-MOmentum Open-label Period Versus Azathioprine and Immunosuppressants and Versus Placebo in Patients with NMOSD

Author:Cree, Bruce   Suero, Beatrice   Walsh, Sarah   Marignier, Romain   Lindsey, John   Kim, Ho Jin   She, Dewei   Cimbora, Daniel   Patterson, Kristina   Paul, Friedemann   

Session Name:S32: Autoimmune Neurology: NMOSD/MOGAD  

Topic:Autoimmune Neurology  

Program Number:S32.001  

Author Institution:Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA, San Francisco,, CA  Eversana, Burlington, Ontario, Canada, Burlington, ON, Canada  Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuroinflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France, Lyon, France  Division of Multiple Sclerosis and Neuroimmunology, University of Texas Health Science Center at Houston, Houston, TX, USA, Houston, TX  Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea, Goyang, Korea, Republic of  Amgen Research, Amgen Inc, Thousand Oaks, CA, USA, Deerfield, IL  Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universita¨t Berlin and Humboldt-Universita¨t zu Berlin, Berlin, Germany, Berlin, Germany  

  • View Abstract
  • View Disclosure

Long-term Efficacy of Satralizumab in Patients with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Updated Analysis from the Open-label SAkuraMoon Study

Author:Palace, Jacqueline   Traboulsee, Anthony   Saiz, Albert   De Seze, Jérôme   Kleiter, Ingo   Bennett, Jeffrey L.   Stokmaier, Daniela   Klingelschmitt, Gaëlle   Te-ying, Audrey Yeo   Vodopivec, Ivana   Yamamura, Takashi   

Session Name:S32: Autoimmune Neurology: NMOSD/MOGAD  

Topic:Autoimmune Neurology  

Program Number:S32.002  

Author Institution:John Radcliffe Hospital, Oxford, United Kingdom , Oxford, United Kingdom  University of British Columbia, Vancouver, Canada, Vancouver, BC, Canada  Service of Neurology, Hospital Clinic and August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain , Barcelona, Spain  Hautepierre Hospital, Strasbourg, France , Strasbourg, France  Ruhr University Bochum, Bochum, Germany , Bochum, Germany  University of Colorado School of Medicine, Aurora, Colorado, USA, Aurora, CO  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  National Center of Neurology and Psychiatry, Tokyo, Japan, Tokyo, Japan  

  • View Abstract
  • View Disclosure

Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD): Interim Analysis From the Ongoing Phase 3 CHAMPION-NMOSD Trial

Author:Pittock, Sean   Barnett, Michael   Bennett, Jeffrey   Berthele, Achim   De Seze, Jerome   Levy, Michael   Nakashima, Ichiro   Oreja-Guevara, Celia   Palace, Jacqueline   Paul, Friedemann   Pozzilli, Carlo   Mashhoon, Yasmin   Allen, Kerstin   Parks, Becky   Kim, Ho Jin   

Session Name:S32: Autoimmune Neurology: NMOSD/MOGAD  

Topic:Autoimmune Neurology  

Program Number:S32.003  

Author Institution:Mayo Clinic, Rochester, MN  University of Sydney, Camperdown, Australia  University of Colorado, Aurora, CO  School of Medicine, Technical University Munich, Munich, Germany  Strasbourg University Hospital Center, Strasbourg, France  Massachusetts General Hospital/Harvard Medical School, Boston, MA  Tohoku Medical and Pharmaceutical University, Sendai, Japan  San Carlos Clinical Hospital and Complutense University of Madrid, Madrid, Spain  John Radcliffe Hospital, Oxford, United Kingdom  Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany  Sapienza University, Rome, Italy  Alexion, AstraZeneca Rare Disease, Boston, MA  National Cancer Center, Goyang, Korea, Republic of  

  • View Abstract
  • View Disclosure

Evaluation of Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) Levels During Eculizumab and Ravulizumab Treatments in Aquaporin-4-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD)

Author:Wingerchuk, Dean   Bennett, Jeffrey   Berthele, Achim   Clardy, Stacey   Kim, Ho Jin   Nakahara, Jin   De Seze, Jerome   Kinoshita, Makoto   Bou-Chahine, Ruba Deeb   Mashhoon, Yasmin   Parks, Becky   Allen, Kerstin   Thakar, Ketan   Carlin, Dan   Stankowski, Jeannette   Pittock, Sean   

Session Name:S32: Autoimmune Neurology: NMOSD/MOGAD  

Topic:Autoimmune Neurology  

Program Number:S32.004  

Author Institution:Mayo Clinic, Phoenix, Scottsdale, AZ  University of Colorado School of Medicine, Aurora, CO  School of Medicine, Technical University Munich, Muenchen, Germany  University of Utah, Salt Lake City, UT  National Cancer Center, Goyang, Korea, Republic of  Keio University School of Medicine, Shinjuku-ku, Japan  CHU de Strasbourg, Strasbourg, France  Osaka General Medical Center, Osaka, Japan  Alexion, AstraZeneca Rare Disease, Boston, MA  Mayo Clinic, Rochester, Rochester, MN  

  • View Abstract
  • View Disclosure

Association of Cytokine Proteins with Disease Activity in Neuromyelitis Optica Spectrum Disorder Participants Receiving Inebilizumab Treatment

Author:Pittock, Sean   Aktas, Orhan   Kim, Ho Jin   Marignier, Romain   Wingerchuk, Dean   Smith, Micheal   Clarkson, Kristen   Rees, William   Patterson, Kristina   Cree, Bruce   

Session Name:S32: Autoimmune Neurology: NMOSD/MOGAD  

Topic:Autoimmune Neurology  

Program Number:S32.005  

Author Institution:Mayo Clinic and Center for MS and Autoimmune Neurology, Rochester, MN, USA, Rochester, MN  Medical Facility, Heinrich Heine University Du¨sseldorf, Du¨sseldorf, Germany, Düsseldorf, Germany  Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea, Goyang, Korea, Republic of  Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuroinflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France, Lyon, France  Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA , Scottsdale, AZ  Amgen Research, Amgen Inc, Thousand Oaks, CA, USA, Rockville, MD  Amgen Research, Amgen Inc, Thousand Oaks, CA, USA, Deerfield, IL  Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA  

  • View Abstract
  • View Disclosure

Displaying 1 - 5 of 10

  • Page:
  • 1
  • 2

© 2015 Mira Smart Conference | http://www.mirasmart.com